Cue Biopharma Inc (CUE)
1.55
+0.05
(+3.33%)
USD |
NASDAQ |
Nov 14, 11:04
Cue Biopharma Revenue (TTM): 8.296M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 8.296M |
| March 31, 2024 | 7.02M |
| December 31, 2023 | 5.49M |
| September 30, 2023 | 3.82M |
| June 30, 2023 | 1.788M |
| March 31, 2023 | 0.432M |
| December 31, 2022 | 1.245M |
| September 30, 2022 | 9.348M |
| June 30, 2022 | 11.68M |
| March 31, 2022 | 14.39M |
| December 31, 2021 | 14.94M |
| Date | Value |
|---|---|
| September 30, 2021 | 7.162M |
| June 30, 2021 | 5.471M |
| March 31, 2021 | 3.807M |
| December 31, 2020 | 3.154M |
| September 30, 2020 | 3.728M |
| June 30, 2020 | 4.008M |
| March 31, 2020 | 3.988M |
| December 31, 2019 | 3.458M |
| September 30, 2019 | 2.740M |
| June 30, 2019 | 2.205M |
| March 31, 2019 | 1.322M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.432M
Minimum
Mar 2023
14.94M
Maximum
Dec 2021
5.959M
Average
4.008M
Median
Jun 2020
Revenue (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 2.753B |
| Arbutus Biopharma Corp | 6.742M |
| GlycoMimetics Inc | -- |
| FibroGen Inc | 173.82M |
| Cidara Therapeutics Inc | 39.07M |